Trial Profile
The efficacy of switching from sulfonyl urea to repaglinide on glycemic control in elderly patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 16 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record